en.ce.cn 21 Jan, 2023 03:45 am

Sinopharm's mRNA Omicron vaccine gets green light for trials--China Economic Net

China National Biotec Group, a subsidiary of China National Pharmaceutical Group Co Ltd (Sinopharm), announced on Friday that its biotech unit in Shanghai has received regulatory approval for clinical trials of China's first mRNA COVID-19 vaccine targeting the Omicron strains.The approval for Omicron-specific mRNA vaccine clinical trials,granted by the State Drug Administration on Thursday, is a "milestone"in the company's COVID-19 vaccine development after producing inactivated and genetic recombinant vaccines, Zhang Yuntao, vice-president and chief scientist of the group, said in a statement.Also, we have been making efforts to speed up the process for clinical trials," Zhang said.The company added that it will further assess the safety, immunogenicity and effectiveness of production during clinical trials.

Virogin, which is based in Shanghai, has built a research and development platform, as well as production lines with an annual capacity of 2 billion doses of mRNA vaccine.According to the Ministry of Industry and Information Technology, China's annual COVID-19 vaccine production capacity has reached 7 billion doses, and the annual output exceeded 5.

Read full story at en.ce.cn